Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level. Alloy's AntiClastic technology is a proprietary cyclic nucleic acid technology that Alloy and its partners have applied to antisense oligonucleotides (ASOs) to improve the potency of RNase H-mediated decay of mRNA and regulatory RNAs, modulate splicing, and trigger ADAR; to siRNA for improved RNAi; and to sgRNA for gene editing. Alloy Genetic Medicines has integrated AI-based sequence design, oligonucleotide synthesis using validated nucleotide chemistries and QC, drug discovery and preclinical testing, and alliance management to rapidly advance partnered programs from therapeutic concepts to development candidates. AntiClastic development candidates exhibit improved potency and reduced inflammatory responses, resulting in an improved therapeutic index. The Genetic Medicines division has also partnered with Alloy's Antibody P
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- 1 Under-$10 Stock Set to Surge as Much as 963% in 2026 [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $9.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 1/8/26 - Form SCHEDULE
- 12/30/25 - Form S-3
- 12/19/25 - Form 4
- ARCT's page on the SEC website